Clinical trials: Diabetic Macular Oedema
Diabetic Macular Edema (DME), Pars Plana Vitrectomy
SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of SAR 1118 within the anterior and posterior chamber of the eye and plasma in subjects undergoing elective vitrectomy when treated with…
- Trial name
- NCT00936520
- Testing
- SAR 1118 0.1%, SAR 1118 1.0%, SAR 1118 5.0%
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Diabetic Retinopathy
Macular Edema Incidence/Severity Reduction With Nevanac
The purpose of this study is to evaluate NEVANAC in patients with diabetic retinopathy who developed macular edema (ME) within 90 days following cataract surgery.
- Trial name
- NCT00939276
- Testing
- Nepafenac ophthalmic suspension, 0.1% (NEVANAC®), Nepafenac ophthalmic suspension vehicle
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Alcon Research
Diabetic Retinopathy, Diabetic Macular Edema
Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema
Efficacy duration of triamcinolone acetonide (steroid) for treatment of diabetic macular edema. Furthermore, dosage dependency of triamcinolone acetonide comparing a high dosage versus a low dosage.
- Trial name
- NCT00476918
- Testing
- Intravitreal injection (triamcinolone acetonide)
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Heidelberg University
Age - Related Macular Degeneration (AMD), Diabetic Macular Edema
Wide Field OCTA in Ocular Diseases
The main retinal diseases, whether or not associated with specific mutations genetic, cause progressive degeneration of vascular retinal structures and not vascular, resulting in decreased visual function.
- Conditions
- Age - Related Macular Degeneration (AMD), Diabetic Macular Edema, Diabetic Retinopathy, Myopia
- Trial name
- WOOD-2025 (NCT07298174)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Diabetic Macular Edema
Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME)
The primary objective is to demonstrate the non-inferiority of bevacizumab to ranibizumab in the treatment of patients with DME (OCT central area thickness > 275 μm) as determined by the change in best-corrected visual acuity…
- Trial name
- BRDME (NCT01635790)
- Testing
- Ranibizumab, Bevacizumab
- Where
- Netherlands
- Volunteers
- 246 people
- Sponsor
- Prof. dr. R.O. Schlingemann
Diabetic Macular Edema
Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)
A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept
- Trial name
- VERONA (NCT06099184)
- Testing
- EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Diabetic Retinopathy
High Blood Pressure and Sleep Apnea in Diabetic Macular Edema
Macular edema remains a major cause of vision impairment in diabetic patients. Its pathogenesis is multifactorial and incompletely understood.
- Trial name
- OMHADIA (NCT00970723)
- Testing
- high blood pressure treatment, sleep apnea treatment, diabetic macular edema treatment
- Where
- 5 sites in France
- Volunteers
- 86 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diabetic Retinopathy, Macular Edema
20- Versus 23- Gauge System for Pars Plana Vitrectomy
The aim of the present study is to compare the functional and clinical differences and advantages between a standard operating system and a newly developed even smaller system for pars plana vitrectomy.
- Conditions
- Diabetic Retinopathy, Macular Edema, Postoperative Complications, Vitreous Hemorrhage
- Trial name
- NCT00411970
- Testing
- 20- and 23 gauge vitreoretinal surgery systems
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Diabetic Retinopathy, Diabetic Macular Edema
Anti-VEGF Treatment for Prevention of PDR/DME
Multiple studies have implicated vascular endothelial growth factor VEGF as a major causative factor in human eye diseases characterized by neovascularization including proliferative diabetic retinopathy (PDR) and vascular…
- Trial name
- NCT02634333
- Testing
- Prompt aflibercept, Deferred laser, Deferred aflibercept
- Where
- 85 sites in United States, Canada
- Volunteers
- 399 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Macular Edema
MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2)
The objective of this study is to investigate if the drug ranibizumab administrated by microdose injection into the eye is safe and effective to treat diabetic macular edema.
- Trial name
- MINIMA-2 (NCT01112085)
- Testing
- Ranibizumab 0.05mg, Ranibizumab 0.5mg
- Where
- 6 sites in Argentina, Mexico
- Volunteers
- 72 people
- Sponsor
- Especialistas en Retina Medica y Quirurgica Grupo de Investigacion
Diabetic Macular Edema
Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation at various doses in patients with diabetic macular edema.
- Trial name
- NCT00656643
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Santen Inc.
Diabetic Macular Edema
Mean Visual Acuity Changes Following Five Injections of Aflibercept
Diabetic Macular Edema is a serious ocular consequence of poorly controlled diabetes. Even though significant research has been done to clarify the pathogenesis of DME, a clear causal pathway of the complication is of yet…
- Trial name
- NCT02645266
- Testing
- Aflibercept Injection [Eylea]
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- McMaster University
Diabetic Macular Edema
A Single Ascending Dose Cohort Study of AG-73305 in DME Patients
This is a multi-centered, open-labeled, single ascending-dose-cohort study to evaluate the safety and efficacy of 4 dose cohorts of AG-73305 administered by intravitreal injection in patients with diabetic macular edema (DME).
- Trial name
- NCT05301751
- Testing
- AG-73305
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Allgenesis Biotherapeutics Inc.
Diabetic Macular Edema
Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular Edema
Purpose: To compare the effects of macular photocoagulation with or without intravitreal bevacizumab (IVB) or triamcinolone (IVTA) for the treatment of diabetic macular edema (DME).
- Trial name
- IBeTA (NCT02310295)
- Testing
- Laser, Bevacizumab, Triamcinolone Acetonide
- Volunteers
- 45 people
- Sponsor
- University of Sao Paulo
Diabetic Macular Edema, Visual Acuity
Treatment of Refractory Diabetic Macular Edema With Infliximab
The purpose of this study is to determine if treatment with infliximab improves macular edema which is refractory to laser photocoagulation in patients with diabetes.
- Conditions
- Diabetic Macular Edema, Visual Acuity, Diabetic Retinopathy
- Trial name
- NCT00505947
- Testing
- infliximab
- Where
- 2 sites in Greece
- Volunteers
- 12 people
- Sponsor
- University of Athens
Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation
VISUPRIME® Eye Drops
The study purpose is to assess the efficacy of VISUPRIME® eye drops in preventing the conjunctival bacterial load in patients undergoing to anti-VEGF injection.
- Conditions
- Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT05677685
- Testing
- VISUPRIME
- Where
- 6 sites in Italy
- Volunteers
- 78 people
- Sponsor
- VISUfarma SpA
Diabetic Macular Edema
Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study
Primary Objective: To collect post-approval safety data related to intraocular pressure (IOP) after one or more injections of Iluvien as standard of care in subjects with diabetic macular edema (DME).
- Trial name
- FAD (NCT02902744)
- Testing
- ILUVIEN®
- Where
- United States
- Sponsor
- Johns Hopkins University
Diabetic Retinal Edema
Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser
Long-term follow-up of patients with diabetic macular edema (DME) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) combined focal laser and identification of prognostic morphological characteristics.
- Trial name
- NCT03590444
- Testing
- Ranibizumab 0.5 MG/0.05 ML Intraocular Solution
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Hospital Hietzing
Diabetic Macular Edema
Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema
To evaluate the safety of intravitreal ranibizumab repeated injections in patients with diabetic macular edema regarding maintenance of retinal ganglion cell function.
- Trial name
- NCT02055911
- Testing
- Ranibizumab
- Where
- Brazil
- Sponsor
- Federal University of São Paulo
Diabetic Macular Edema, Age-Related Macular Degeneration
Effect of Corona Virus on Intravitreal Injections
During pandemic of corona virus, patients compliance may be affected. We aim to study the factors lead to unregulated visits and its implications on the final visual outcome.
- Conditions
- Diabetic Macular Edema, Age-Related Macular Degeneration, Choroidal Neovascularization, Myopic Choroidal Neovascularisation
- Trial name
- NCT05494775
- Testing
- Anti-vascular endothelial growth factors (Anti-VEGFs)
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Benha University